Linezolid-Induced Pancytopenia in Patients Using Dapagliflozin: A Case Series

References

• Katip W, Oberdorfer P, Monocentric Retrospective A. Study of AUC/MIC ratio of vancomycin associated with clinical outcomes and nephrotoxicity in patients withEnterococcal infections. Pharmaceutics. 2021;13(9):1378. doi:10.3390/pharmaceutics13091378
   PubMed Web of Science ®Google Scholar
• Katip W, Okonogi S, Oberdorfer P. The thirty-day mortality rate and nephrotoxicity associated with trough serum vancomycin concentrations during treatment of enterococcal infections: a propensity score matching analysis. Front Pharmacol. 2022;12:773994. doi:10.3389/fphar.2021.773994
   PubMed Web of Science ®Google Scholar
• Batts DH. Linezolid-A new option for treating Gram-positive infections. Oncology. 2000;14(8):23–29.
   Google Scholar
• Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, Tarpley WG. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol. 2001;1(5):470–476. doi:10.1016/S1471-4892(01)00082-0
   PubMedGoogle Scholar
• Hirano R, Sakamoto Y, Tachibana N, et al. Retrospective analysis of the risk factors for the linezolid-induced thrombocytopenia in adult Japanese patients. Int J Clin Pharm. 2014;36:795–799. doi:10.1007/s11096-014-9961-6
   PubMed Web of Science ®Google Scholar
• Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34(5):695–698. doi:10.1086/338403
   PubMed Web of Science ®Google Scholar
• Chen C, Guo DH, Cao X, et al. Risk factors for thrombocytopenia in adult Chinese patients receiving linezolid therapy. Curr Ther Res Clin Exp. 2012;73(6):195–206. doi:10.1016/j.curtheres.2012.07.002
   PubMed Web of Science ®Google Scholar
• Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126–2133. doi:10.1016/j.clinthera.2009.10.017
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72. doi:10.1086/498509
   PubMed Web of Science ®Google Scholar
• Sasaki T, Takane H, Ogawa K, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55(5):1867–1873. doi:10.1128/AAC.01185-10
   PubMed Web of Science ®Google Scholar
• Singhania SVK, Shenoy S, Kapoor D. Linezolid-induced rare triad of hypoglycaemia, bone marrow suppression and hyponatraemia in elderly. J Clin Pharm Ther. 2020;45(2):376–378. doi:10.1111/jcpt.13069
   Web of Science ®Google Scholar
• Sohita D. Dapagliflozin: a review in type 2 diabetes. Drugs. 2019;79(10):1135–1146. doi:10.1007/s40265-019-01148-3
   Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829. doi:10.1016/S0140-6736(20)31824-9
   PubMed Web of Science ®Google Scholar
• Kishor K, Dhasmana N, Kamble SS, et al. Linezolid induced adverse drug reactions - an update. Curr Drug Metab. 2015;16(7):553–559. doi:10.2174/1389200216666151001121004
   PubMed Web of Science ®Google Scholar
• Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382(10):893–902. doi:10.1056/NEJMoa1901814
   PubMed Web of Science ®Google Scholar
• Carey PJ. Drug-induced myelosuppression: diagnosis and management. Drug Saf. 2003;26(10):691–706. doi:10.2165/00002018-200326100-00003
   PubMed Web of Science ®Google Scholar
• Fujii S, Muraoka S, Miyamoto A, et al. Linezolid-induced apoptosis through mitochondrial damage and role of superoxide dismutase-1 in human monocytic cell line U937. Yakugaku Zasshi. 2018;138(1):73–81. doi:10.1248/yakushi.17-00133
   Web of Science ®Google Scholar
• Leach KL, Swaney SM, Colca JR, et al. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007;26(3):393–402. doi:10.1016/j.molcel.2007.04.005
   PubMed Web of Science ®Google Scholar
• Nagiec EE, Wu L, Swaney SM, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother. 2005;49(9):3896–3902. doi:10.1128/AAC.49.9.3896-3902.2005
   PubMed Web of Science ®Google Scholar
• Tsai KL, Hsieh PL, Chou WC, Cheng HC, Huang YT, Chan SH. Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK. Cell Biosci. 2021;11(1):44. doi:10.1186/s13578-021-00547-y
   Web of Science ®Google Scholar
• Hanai Y, Matsuo K, Ogawa M, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 2016;22(8):536–542. doi:10.1016/j.jiac.2016.05.003
   PubMed Web of Science ®Google Scholar
• Ikuta S, Tanimura K, Yasui C, et al. Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery. J Infect Chemother. 2011;17:388–391. doi:10.1007/s10156-010-0188-8
   PubMed Web of Science ®Google Scholar
• Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol. 2003;14:795–801. doi:10.1093/annonc/mdg211
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Holford NHG, Kasai H, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Clin Pharmacol. 2017;83(8):1758–1772.
   Google Scholar
• Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17:70–75. doi:10.1007/s10156-010-0080-6
   PubMed Web of Science ®Google Scholar
• Leader R, Hackett J, Allan A, Carter P. Linezolid-induced pancytopenia. BMJ Case Rep. 2018;2018:225480.
   Google Scholar
• Lee EY, Caffrey AR. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother. 2017;62(1):e01453–e01517. doi:10.1128/AAC.01453-17
   PubMed Web of Science ®Google Scholar
• Ballesteros MDM, Milián MEO, Velázquez ED, et al. Myelosupression induced by linezolid: a pediatric case. Arch Argent Pediatr. 2017;115(6):e420–e423. doi:10.5546/aap.2017.e420
   Web of Science ®Google Scholar
• Parlak E, Tan H. Pancytopenia due to linezolid treatment. Turk Pediatri Ars. 2015;50(3):185–188. doi:10.5152/TurkPediatriArs.2015.1133
   Google Scholar
• Varkal G, Paydas S, Gural MC, et al. Pancytopenia associated with linezolid therapy in a hemodialysis patient. Turk Nephrol Dial Transplant J. 2017;26(1):121–123. doi:10.5262/tndt.2017.1001.21
   Google Scholar
• N Lakhani, W Thompson. Probable linezolid-induced pancytopenia. Can J Infect Dis Med Microbiol. 2005;16(5):286–288. doi:10.1155/2005/961613
   Google Scholar
• Sharma S, Syal A, Gupta M, et al. Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant staphylococcus aureus. Cureus. 2020;12(10):e10890. doi:10.7759/cureus.10890
   Web of Science ®Google Scholar
• Kraleti S, Soultanova I. Pancytopenia and lactic acidosis associated with linezolid use in a patient with empyema. J Ark Med Soc. 2013;110(4):62–63.
   PubMedGoogle Scholar
• Yulin Z, Lingti K, Shan G, Yong Z. A possible interaction between linezolid and digoxin: a case report of therapeutic drug monitoring. Saudi Pharm J. 2020;28(11):1408–1410. doi:10.1016/j.jsps.2020.09.005
   Web of Science ®Google Scholar